Palisade Total Stockholder Equity from 2010 to 2024

PALI Stock  USD 2.42  0.02  0.83%   
Palisade Bio's Total Stockholder Equity is increasing with very volatile movements from year to year. Total Stockholder Equity is predicted to flatten to about 6.2 M. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2006-06-30
Previous Quarter
9.9 M
Current Value
6.6 M
Quarterly Volatility
M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Palisade Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Palisade Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 K, Interest Expense of 14.2 K or Selling General Administrative of 6.6 M, as well as many indicators such as Price To Sales Ratio of 17.64, Dividend Yield of 0.0 or PTB Ratio of 0.34. Palisade financial statements analysis is a perfect complement when working with Palisade Bio Valuation or Volatility modules.
  
Check out the analysis of Palisade Bio Correlation against competitors.
For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.

Latest Palisade Bio's Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Palisade Bio over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Palisade Bio's Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Palisade Bio's overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Very volatile
   Total Stockholder Equity   
       Timeline  

Palisade Total Stockholder Equity Regression Statistics

Arithmetic Mean6,201,396
Coefficient Of Variation122.02
Mean Deviation4,600,254
Median6,972,633
Standard Deviation7,567,159
Sample Variance57.3T
Range34.3M
R-Value0.01
Mean Square Error61.7T
R-Squared0.0001
Significance0.97
Slope19,747
Total Sum of Squares801.7T

Palisade Total Stockholder Equity History

20246.2 M
202311.3 M
202212.5 M
20217.4 M
2020-16.6 M
20195.1 M
2018M

About Palisade Bio Financial Statements

Investors use fundamental indicators, such as Palisade Bio's Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Palisade Bio's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Total Stockholder Equity11.3 M6.2 M

Currently Active Assets on Macroaxis

When determining whether Palisade Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Palisade Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Palisade Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Palisade Bio Stock:
Check out the analysis of Palisade Bio Correlation against competitors.
For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palisade Bio. If investors know Palisade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(13.26)
Return On Assets
(0.59)
Return On Equity
(1.10)
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palisade Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Palisade Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palisade Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.